News

On 19 March, the 4th edition of the Transatlantic Exchanges took place in Paris—a scientific day co-organised by Gustave Roussy and the Dana-Farber Cancer Institute with support from the Servier Institute. Dr. Toni Choueiri (Dana-Farber) and Prof. Karim Fizazi (Gustave Roussy), co-chairs of the event, reflect on the key themes of this edition,...

Named Gustave Roussy International Egypt, the opening of a cancer centre in Cairo, Egypt, marks the transformation of the Dar Al-Salam-Hermel Oncology Hospital under a brand licensing agreement with Gustave Roussy International, a subsidiary of Gustave Roussy.

In 2024, the Nuclear Safety and Radiation Protection Authority (ASNR) and the Regional Health Agency (ARS) Île-de-France authorised Gustave Roussy to conduct Phase I trials in nuclear medicine, the first stage in the clinical validation process of a new treatment.

Pragmatic trials are simple, affordable trials aiming to inform or change practice broadly. Prof Alexandra Leary, MD, Ph.D., a medical oncologist at Gustave Roussy and deputy head of the Medical Oncology Department, explains these trials in five questions.

Gustave Roussy and the Dana-Farber Cancer Institute (Boston, United States) are organising the fourth edition of the Transatlantic Exchange oncology conference on 19 March 2025 at the Hyatt Regency Paris Étoile hotel. The theme will be “Radiopharmaceutical Therapy Meets Oncology.”

Unveiled on World Cancer Day, February 4, 2025, Gustave Roussy’s latest campaign delivers a powerful message of hope and scientific progress.

The laying of the foundation stone marks a decisive milestone in developing the Paris-Saclay Cancer Cluster, which is currently being established around Gustave Roussy and is set to become the largest oncology hub in Europe.

A medical oncologist at Gustave Roussy and director of the personalised prevention program Interception, Dr. Suzette Delaloge has been honoured by the Ruban Rose Association for her research aimed at developing a saliva test capable of detecting early signs of breast cancer.

Each year, Clarivate / Web of Science publishes a list of the most cited researchers worldwide, categorized into 21 fields. Once again, Gustave Roussy and its Foundation rank among the most represented French institutions, reflecting its research's excellence and global influence.

The Institute has launched the Gustave Roussy Prize to mark the 150th anniversary of the birth of its visionary founder. With an endowment of €200,000, this scientific award will annually recognize a researcher whose discoveries in the fight against cancer have a major impact on patient care.